August 1, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) shares over potential securities laws violations by Invivo Therapeutics Holdings and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) concerning whether a series of statements by Invivo Therapeutics Holdings regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Invivo Therapeutics Holdings Corp, formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. Invivo Therapeutics Holdings Corp (reported that its Net Loss declined from $33.31 million in 2015 to $23.44 million in 2016.

On July 31, 2017, Invivo Therapeutics Holdings Corp revealed that after a third patient death, it had stopped a trial of its Neuro-Spinal Scaffold, a spinal cord injury treatment and advised investors that the it had decided to stop the trial while it discusses with the U.S. Food and Drug Administration whether to change the trial's enrollment criteria.